Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Axalimogene filolisbac - Advaxis

Drug Profile

Axalimogene filolisbac - Advaxis

Alternative Names: ADXS HPV; ADXS-11-001; ADXS11-001-vaccine; Anal-cancer-vaccine-Advexis; AXAL; Cervical cancer vaccine - Advaxis; Head and neck cancer vaccine - Advaxis; Listeria cancer vaccine - Advaxis; Listeria monocytogenes vaccine live attenuated - Advaxis; Live attenuated listeria monocytogenes vaccine - Advaxis; Lm-Listeriolysin-O-fetal liver kinase-1; Lm-LLO-E7; Lm-LLO-E7 vaccine; Lovaxin-C; NSC-752718; Raligize

Latest Information Update: 02 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Advaxis
  • Developer Advaxis; Brown University Medical School; Cancer Research UK; Gynecologic Oncology Group; Icahn School of Medicine at Mount Sinai; MedImmune
  • Class Cancer vaccines; Gene therapies
  • Mechanism of Action Gene transference; Human papillomavirus E7 protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anal cancer; Cervical cancer; Head and neck cancer
  • New Molecular Entity No
  • Available For Licensing Yes - Cervical cancer

Highest Development Phases

  • Phase III Cervical cancer
  • Phase II Anal cancer; Oropharyngeal cancer
  • Suspended Head and neck cancer
  • Discontinued Cervical intraepithelial neoplasia

Most Recent Events

  • 24 Oct 2019 Global BioPharma plans a phase II trial for HPV-associated Non-small cell lung cancer by the end of 2019
  • 28 Jun 2019 Advaxis initiates terminates the phase III AIM2CERV trial for Cervical cancer (Metastatic disease, Recurrent, Second-line therapy or greater) in Argentina, Brazil, Canada, Chile, Malaysia, Mexico, Netherlands, Poland, Romania, Russia, Serbia, South Korea, Spain, Taiwan, Ukraine, and in USA
  • 16 May 2019 The US FDA lifts partial clinical hold from phase III AIM2CERV trial in Cervical cancer (Metastatic disease, Second-line therapy or greater) (NCT02853604)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top